Diamante, a Verona, Italy-based biotechnology company focused on the use of plants for producing value-added molecules, raised $595K in Seed funding.
The round was led by Arieli Capital with participation from Elena Paola Lanati and associations Angels4Women and Angels4Impact.
The company intends to use the funds to scale into the US and begin an FDA approval process.
Led by CEO Valentina Garonzi, CSO Roberta Zampieri, and Linda Avesani, Diamante is providing a novel therapeutic approach toward autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Its main asset is a specific therapeutic solution for Rheumatoid Arthritis (RA). Its technology leverages plant viruses for the production of virus nanoparticles (VNPs) and an innovative therapeutic approach based on the specific induction of the immunological tolerance through the use of specific autoantigenic peptides.
FinSMEs
17/01/2023